^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    ICOSLG overexpression

    i
    Other names: ICOSLG, Inducible T Cell Costimulator Ligand, B7RP-1, B7-H2, B7RP1, B7H2, B7-Related Protein 1, B7 Homolog 2, KIAA0653, ICOS-L, CD275, ICOSL, GL50, B7h, B7-Like Protein Gl50, B7 Homologue 2, ICOS Ligand, Transmembrane Protein B7-H2 ICOS Ligand, Inducible T-Cell Costimulator Ligand, CD275 Antigen, LICOS
    Entrez ID:
    23308
    Related biomarkers:
    Expression
    4ms
    ICOSLG acts as an oncogene to promote glycolysis, proliferation, migration, and invasion in gastric cancer cells. (PubMed, Arch Biochem Biophys)
    miR-331-3p, which is downregulated in GC tissues, functions as a negative regulator of ICOSLG4. Targeting miR-331-3p/ICOSLG4 axis could potentially suppress GC progression.
    Journal
    |
    ICOS (Inducible T Cell Costimulator) • ICOSLG (Inducible T Cell Costimulator Ligand) • MIR331 (MicroRNA 331)
    |
    ICOSLG overexpression
    1year
    Non-invasive detection of plasma proteins in immune checkpoint inhibitor-treated patients with advanced non-small cell lung cancer (AACR 2023)
    These findings suggest that the expression of FasL and ICOSLG at baseline may help identify patients who will respond to treatment with pembrolizumab.
    Clinical • Checkpoint inhibition • PD(L)-1 Biomarker • IO biomarker • Metastases
    |
    FASLG (Fas ligand) • ICOS (Inducible T Cell Costimulator) • ICOSLG (Inducible T Cell Costimulator Ligand) • FAS (Fas cell surface death receptor)
    |
    ICOSLG overexpression • FAS overexpression • FASLG overexpression + ICOSLG overexpression
    |
    Keytruda (pembrolizumab)